
Topic
HER2-Positive Metastatic Breast Cancer
Podcasts
Tumor Board # 81Sep 15, 2026CNS Disease in Breast Cancer: Clinical Management & Strategies

How should a breast cancer team manage central nervous system (CNS) disease now that systemic therapy, radiation, and surgery all compete for the first move? On this episode of BackTable Tumor Board, host Dr. Lindsay Peterson interviews Dr. Barbara O'Brien, neuro-oncologist at MD Anderson, about diagnosis, sequencing, and follow-up for CNS disease in breast cancer. They discuss risk by subtype, when to image and screen, and the importance of multidisciplinary workup for new brain metastases, as well as how to choose and sequence local and systemic options.
Tumor Board # 52Mar 24, 2026Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer

Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful attention to toxicity. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Sara Nunnery review the role of ADCs in HER2-positive disease and their growing application in HER2-low and HER2-ultralow metastatic settings.
Tumor Board # 48Feb 17, 2026HER2-Positive Metastatic Breast Cancer: Treatment Insights & Protocols

In a patient with metastatic HER2-positive breast cancer, what should guide the next decision: trial data, toxicity, or durability of response? In this episode of BackTable Tumor Board, Dr. Lindsay Peterson (Washington University) sits down with Dr. Erica Hamilton (Sarah Cannon Research Institute) to examine how next-generation HER2-directed therapies are reshaping the management of metastatic disease. As treatment options expand beyond trastuzumab-based regimens to agents such as trastuzumab deruxtecan and tucatinib, clinical decision-making increasingly hinges on sequencing strategy, interpretation of evolving trial data, and thoughtful toxicity management.